The U.K. removes Keytruda from Cancer Drug Fund in bladder cancer indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

England’s National Institute for Health and Care Excellence has rejected Keytruda (pembrolizumab) in patients who receive locally advanced or metastatic urothelial carcinoma who have had platinum-containing chemotherapy.

Merck sponsors Keytruda.

The drug has since been removed from the Cancer Drug Fund, where it was available previously.

The National Institute for Health and Care Excellence said it couldn’t recommend the drug because of cost-effectiveness.

YOU MAY BE INTERESTED IN

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login